Advanced Filters
noise

fabry-disease Clinical Trials

A listing of fabry-disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 37 clinical trials
S Site Contact

A Study of Replagal in Children and Adults With Fabry Disease in India

The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.

years of age All Phase 4
L Lei Yin, PhD

Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease

Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease

7 years of age All Phase N/A
Q Qian Shen, MD,PhD

Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease

This is a single-arm, open label, single-dose clinical study to evaluate the safety, tolerability and efficacy of BBM-F101 injection in the pediatric Fabry disease participants up to 52 weeks after infusion, and the long-term safety and efficacy of BBM-F101 injection up to 5 years after infusion. BBM-F101 injection is an …

7 - 18 years of age All Phase N/A

Evaluation of a Screening Strategy of Fabry Disease in Patient With Renal Biopsy

Fabry disease is genetic X linked disease, with annual incidence of 1 in 100,000 that is certainly underestimate the true prevalence of the disease. Renal biopsy in some patients does not allow determining the etiology of nephropathy. It is why investigators would like to evaluate the screening of Fabry patients …

18 years of age All Phase N/A

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

18 years of age All Phase 1/2
C Chiara Leuzzi, MD

Italian Anderson Fabry Disease Cardiovascular Registry

The RICMAF Study is an observational, multicenter, non-pharmacological study conducted in Italy. Although Anderson-Fabry Disease (AFD) is rare, it is likely underdiagnosed due to its nonspecific symptoms, leading to delays in proper treatment. The RICMAF Study aims to improve understanding of AFD, especially its cardiac manifestations, which are a major …

2 years of age All Phase N/A

Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

years of age All Phase N/A
M Mark R. Iwanochko, MD, FRCPC

Canadian Fabry Disease Initiative (CFDI) National Registry

CFDI NATIONAL REGISTRY Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic …

5 - 85 years of age All Phase N/A
I Irina Schumacher

Evaluation of HEArt invoLvement in Patients With FABRY Disease

This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.

18 years of age All Phase N/A
Z Zhaang, Xinyu

Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy

The purpose of this study was to understand the epidemiological status of Fabry in patients with hypertrophic cardiomyopathy or left ventricular hypertrophy through multi-center early identification of high-risk patients in cardiology according to high-risk profiles, supplemented by DBS (dried blood disc) screening tools, and to explore the screening and diagnosis …

18 years of age All Phase N/A

Simplify language using AI